Page 2 of 612345...Last »

And Cancer Research UK predicting that the lifetime risk of cancer will reach 50 percent by 2027.

‘Inside our Lymphocyte Genome Sensitivity assay, lymphocyte samples are embedded at different depths within the agar gel and irradiated with UVA in vitro. Since UVA-induced genetic damage is intensity dependent, spreading the lymphocytes 3-dimensionally within the agar means we can subject matter the cells to differing UVA intensities conveniently. Then, analysing comet tail fluorescence and length intensity determines the genomic responses to UVA.’ Automatic analysis of every comet's %age tail DNA and Olive Tail Moment – a way of measuring comet tail size multiplied by the strength of fluorescence – for each and every treatment at every depth is completed by Andor's Komet software. Continue reading

A united group of investigators at Simon Fraser University in Burnaby.

Most drug-resistance tumor cells develop this unfortunate characteristic due to a drug-pumping protein known as P-glycoprotein. Now, a united group of investigators at Simon Fraser University in Burnaby, British Columbia, is rolling out a microfluidic chip that can trap individual malignancy cells and investigate the ability of various pump-blocking medications to overcome drug level of resistance. This new lab-on-a-chip device could prove useful for learning multiple drug resistance and for selecting the appropriate therapy for a given patient. Related StoriesStudy displays why malignancy anemia therapy stimulates tumor growthDiscovery may open new doors to focusing on how melanoma grows and spreadsUCLA Wellness adopts GenomOncology's GO Clinical Workbench to accelerate analysis for tumor DNA profiling testsPaul Li, Ph.D., and his colleagues developed the dime-size chip to select and retain individual cancers cells within a chamber which can be dosed with medications loaded into an on-chip reservoir. Continue reading

The Phnom Penh Post reports.

Copyright 2009 Advisory Table Kaiser and Company Family members Foundation. All rights reserved.. Cambodian health officials expand HIV/AIDS prevention education to principal schools The Cambodian Ministry of Health has begun training primary education teachers in 12 provinces on HIV/AIDS prevention education, the Phnom Penh Post reports. Health officials said that although kids in primary school are not regarded as a high-risk inhabitants, they need to become educated on the disease. Mean Chhi Vun – – director of the National Middle for HIV/AIDS, Dermatology and STDs – – said the training students ‘certainly are a group of people we have to focus on because they. Would be the backbone of the country.’ Secondary-school aged students currently are receiving HIV/AIDS education, and the scheduled applications are being utilized as a model for the new primary school initiative, according to Pen Saroeun, director of the Ministry of Education’s School Wellness Department. Continue reading

Cases of meningitis caused by herpes simplex virus set to rise Viral meningitis is usually common.

The latest epidemic among young adults was connected with a lot more than 100 cases of mumps meningitis in England in 2004-6.. Cases of meningitis caused by herpes simplex virus set to rise Viral meningitis is usually common, but many instances go unreported, say researchers in this week’s BMJ. And due to the raising incidence of genital herpes in the UK, cases of meningitis caused by the herpes simplex virus are set to go up, they warn. In 2005-6, 2898 people were admitted to hospital in England with a analysis of viral meningitis, however that is 10 times the number of instances notified to the Health Protection Agency in both England and Wales over the same period. Continue reading

Offers announced that it has received 510 clearance from the U.

Food and Medication Administration to advertise its innovative 5-Fluorouracil-covered Central Venous Catheter in the United States. The 5-FU CVC represents our first drug-eluting medical device product to end up being researched and developed totally in-house by Angiotech’s R & D and clinical groups, without the aid of a corporate partner, said Dr. William Hunter, President and CEO of Angiotech. This is definitely an important milestone in our Company’s background, and we look forward to getting into the commercial stage of our 5-FU CVC product, in addition to developing other implantable gadgets that use this novel and proprietary anti-infective technology platform. Related StoriesGastric balloon in a tablet helps patients lose fat without surgery or endoscopyMycobacterium could possibly be more effective in dealing with superficial bladder cancers, study findsMiriam Hospital enrolling local participants for Parachute implant scientific trial to take care of heart failureThe medical data from Angiotech’s 960 patient clinical trial comparing its 5-FU CVC with a chlorhexidine/silver sulfadiazine covered CVC was recently presented by clinical investigators at the 28th International Symposium on Intensive Treatment and Emergency Medicine in Brussels. Continue reading

Page 2 of 612345...Last »